A phase I clinical trial of human embryonic stem cell‐derived retinal pigment epithelial cells for early‐stage Stargardt macular degeneration: 5‐years' follow‐up
Cell Proliferation2021Vol. 54(9), pp. e13100–e13100
Citations Over TimeTop 10% of 2021 papers
Shiying Li, Yong Liu, Lei Wang, Lei Wang, Fang Wang, Tongtao Zhao, Qiyou Li, Haiwei Xu, Xiaohong Meng, Jie Hao, Qi Zhou, Liu Wang, Liu Wang, Zhengqin Yin
Abstract
Subretinal transplantation of hESC-RPE in early-stage STGD1 is safe and tolerated in the long term. Further investigation is needed for choosing proper subjects according to the multi-model image and function assessments.
Related Papers
- → Expression of ABCA4 in the retinal pigment epithelium and its implications for Stargardt macular degeneration(2018)159 cited
- Retinal pigment epithelium (RPE) pigmentary changes are associated with progression from early to advanced age-related macular degeneration (AMD) independent of CFH and ARMS2 risk genotypes.(2020)
- Elucidating the role of Retinal Pigment Epithelium (RPE)-specific ABCA4 in Stargardt disease(2016)
- Localization of ABCA4 in the Retinal Pigment Epithelium and its implications for Stargardt Disease(2018)
- → Peer Review #1 of "Ultrastructural alterations in the retinal pigment epithelium and photoreceptors of a Stargardt patient and three Stargardt mouse models: indication for the central role of RPE melanin in oxidative stress (v0.1)"(2018)